Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380933 | 1.00 | HCAR2 (0.69) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL7893859 | 0.82 | HCAR2 (1.00) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL660178 | 0.82 | HCAR2 (1.00) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL564789 | 0.82 | HCAR2 (1.00) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL28981304 | 0.80 | HCAR2 (0.69) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL3513899 | 0.80 | HCAR2 (0.69) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL6832853 | 0.80 | HCAR2 (0.69) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| Hydrochloric Acid SCHEMBL9261463 | 0.80 | HCAR2 (0.96) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL13692335 | 0.80 | HCAR2 (0.69) | HCAR2MAPTALOX5ALDH1A1MAOA | |
| SCHEMBL14504206 | 0.78 | HCAR2 (0.56) | HCAR2MAPTALOX5ALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022225045-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CACHEXIA ACCOMPANIED BY GHRELIN RESISTANCE | 東レ株式会社 | 2022-10-27 | — | — | WO | claimed |
| CN-1217943-C | New use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | CN | claimed |
| CN-1423651-A | Novel use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2003-06-11 | — | — | CN | claimed |
| CN-117177772-A | Therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance | 东丽株式会社 | 2023-12-05 | — | — | CN | disclosed |
| CN-115768430-A | Ameliorating or preventing agent for muscle strength decline symptoms in diseases or syndromes accompanied by metabolic disorders | 东丽株式会社 | 2023-03-07 | — | — | CN | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20100247938-A1 | MATERIAL FOR THREE-DIMENSIONAL MODELING, PROCESS FOR PRODUCING THREE-DIMENSIONAL MODEL, AND THREE-DIMENSIONAL MODEL | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| WO-2008109238-A1 | SUBSTITUTED CYCLOPENTYL PIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| CN-1217943-C | New use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | CN | disclosed |
| CN-1423651-A | Novel use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2003-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | HCAR2 2357/4885MAPT 1673/4885ALOX5 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.